These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 14984485

  • 21. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group.
    Lancet; ; 365(9453):60-2. PubMed ID: 15639680
    [Abstract] [Full Text] [Related]

  • 22. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G, Verma S, Trudeau M.
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [Abstract] [Full Text] [Related]

  • 23. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
    Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M.
    Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
    [Abstract] [Full Text] [Related]

  • 24. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 25. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV.
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [Abstract] [Full Text] [Related]

  • 26. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
    Doggrell SA.
    Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
    [Abstract] [Full Text] [Related]

  • 27. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM.
    Am J Hosp Palliat Care; 2004 Jun; 21(6):457-65. PubMed ID: 15612238
    [Abstract] [Full Text] [Related]

  • 28. [The ATAC study on adjuvants in breast cancer].
    Bravi S.
    Suppl Tumori; 2004 Jun; 3(4):S15. PubMed ID: 15206200
    [No Abstract] [Full Text] [Related]

  • 29. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A.
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [Abstract] [Full Text] [Related]

  • 30. Anastrozole.
    Cuzick J.
    Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
    [Abstract] [Full Text] [Related]

  • 31. Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
    Jonat W.
    Oncology; 1997 Apr; 54 Suppl 2():15-8. PubMed ID: 9394855
    [Abstract] [Full Text] [Related]

  • 32. Anastrozole: in early breast cancer.
    Wellington K, Faulds DM.
    Drugs; 2002 Apr; 62(17):2483-90; discussion 2491-2. PubMed ID: 12421108
    [Abstract] [Full Text] [Related]

  • 33. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
    Dranitsaris G, Leung P, Mather J, Oza A.
    Anticancer Drugs; 2000 Aug; 11(7):591-601. PubMed ID: 11036964
    [Abstract] [Full Text] [Related]

  • 34. Aromatase inhibitors in breast cancer: an update.
    Lake DE, Hudis C.
    Cancer Control; 2002 Aug; 9(6):490-8. PubMed ID: 12514567
    [Abstract] [Full Text] [Related]

  • 35. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    Brodie AH, Mouridsen HT.
    Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
    [Abstract] [Full Text] [Related]

  • 36. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R.
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [Abstract] [Full Text] [Related]

  • 37. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS, Forbes JF.
    Breast Cancer Res Treat; 2003 Oct; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [Abstract] [Full Text] [Related]

  • 38. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
    Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L, Trial 0020 Investigators, Trial 0021 Investigators.
    Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
    [Abstract] [Full Text] [Related]

  • 39. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ.
    Clin Ther; 2002 May; 24 Suppl C():C3-25. PubMed ID: 12117074
    [Abstract] [Full Text] [Related]

  • 40. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
    Lønning PE.
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.